SEC Form 13F Summary: Carlyle Group Inc.
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Carlyle Group Inc. for the reporting period ending March 31, 2023. The document discloses the investment manager's holdings of equity securities as of the end of the quarter. It does not contain Carlyle Group's own financial performance data (revenue, profit, or cash flow) but rather details the portfolio of stocks held by the firm.
Key Financial Metrics and Portfolio Composition
The filing lists 30 distinct equity positions. The total value of reported holdings is not explicitly summed in the text, but individual position values are provided. Key observations include:
- Largest Position by Value: ZoomInfo Technologies Inc. ($905,929,609).
- Significant Holdings: Quidelortho Corp ($1,110,077,703 value listed, though share count suggests a potential data anomaly or specific class valuation; shares: 12,460,183), Vitru Ltd ($142,169,680), and GDS Hldgs Ltd ($75,995,171).
- Share Counts: The largest share count is held in ZoomInfo Technologies Inc. (36,662,469 shares).
- Voting Authority: The filing indicates "Sole" voting authority for all listed positions, with no shared or none authority reported.
Material Changes and Portfolio Activity
As this is a quarterly snapshot, the filing does not provide a direct comparison to the prior period's holdings within this specific text block. However, the presence of "New" designations (e.g., Exicure Inc) indicates new positions initiated during the quarter. The filing lists a diverse mix of sectors including biotechnology (e.g., Adicet Bio, Effector Therapeutics), technology (e.g., ZoomInfo, Meta Data Limited), and real estate (e.g., Invitation Homes, CubeSmart).
Guidance, Risks, and Contingencies
Management Commentary: None provided in this filing type. Form 13F is a regulatory disclosure of holdings and does not include management outlook or guidance.
Risks and Contingencies: The filing includes a standard disclaimer stating that the SEC has not reviewed the information for accuracy or completeness. No specific risk factors or contingencies regarding the portfolio are detailed in this table.
Important Facts for Investor Verification
- Portfolio Concentration: Verify the concentration risk associated with the top holdings, particularly ZoomInfo Technologies Inc. and Quidelortho Corp, which represent significant portions of the reported value.
- Biotech Exposure: Note the substantial number of positions in clinical-stage or small-cap biotechnology firms (e.g., Adicet Bio, Aeglea Biotherapeutics, Cymabay Therapeutics), which typically carry higher volatility.
- Data Consistency: Review the valuation of Quidelortho Corp ($1.11B value vs. 12.4M shares) to ensure it aligns with market prices at the reporting date, as the value appears disproportionately high relative to the share count compared to other entries.
- Reporting Scope: Confirm that this filing represents only the equity securities required to be reported under Section 13(f) of the Exchange Act and does not include private equity, debt, or other alternative investments held by Carlyle Group.